Yahoo Italia Ricerca nel Web

Risultati di ricerca

  1. 23 mag 2024 · Local Stories May 23, 2024. Conversations with Diego Cadavid. Today we’d like to introduce you to Diego Cadavid. Hi Diego, it’s an honor to have you on the platform. Thanks for taking the time to share your story with us – to start maybe you can share some of your backstory with our readers.

  2. 14 mag 2024 · We are thrilled that Verge Genomics' CMO Diego Cadavid is presenting at the 3rd Annual ALS Drug Development Summit on May 23rd at 11:30 AM. Diego will share insights on Verge’s groundbreaking proof-of-concept study design to evaluate VRG50635 as a potential novel therapeutic candidate for ALS.

  3. 15 mag 2024 · Diego Cadavid. Regional Sales Manager | FP&A Automation | SaaS. 1mo. Vena Copilot for FP&A harnesses the power of Microsoft Azure and Azure OpenAI Service 🤝 to unlock the strategic potential...

  4. 19 mag 2024 · El elenco del thriller de acción policiaco está formado por Diego Cadavid, Carlos Aragón, Horacio García Rojas, Marcela Guirado, Marco Treviño, Karina Gidi, Enoc Leaño. También participaron los actores Adrián Ladrón, Rodrigo Oviedo, Sandra Hernández y Ximena Ayala.

  5. 21 mag 2024 · Diego Cadavid interpretó a 'Iván Vallejo'. SINOPSIS Como en cada año, Teresa Suárez "La Gaviota" y Carmenza, su madre, viajan al eje cafetero para trabajar en la hacienda Casablanca para recolectar el café cosechado en la segunda época del año, pero para esta visita, será la última que ellas realizan, debido a que ahora ellas serán propietarias de un terreno para cosechar.

  6. 13 mag 2024 · Resumen. Generado por Inteliegenica Artifical (OpenAI) + Google Noticias. + Canal WhatsApp. El reconocido actor colombiano, con una trayectoria consolidada en la industria del entretenimiento, se perfila como la figura ideal para interpretar al legendario cantante de música popular colombiana.

  7. 22 mag 2024 · 7 Analysts. XFOR Stock Overview. A late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. About the company. Rewards. Trading at 91.6% below our estimate of its fair value. Revenue is forecast to grow 48.73% per year. Risk Analysis.